Edgewise Therapeutics Inc expected to post a loss of 43 cents a share - Earnings Preview

Edgewise Therapeutics

19/02/2024 14:15

* Edgewise Therapeutics Inc  EWTX.OQ   EWTX.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 21 (estimated) for the period ending December 31 2023
    *  (Majority is on Total Revenue)
    * ​LSEG's mean analyst estimate for Edgewise Therapeutics
Inc is
for a loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Edgewise
Therapeutics Inc is $25.00​, above​ its last closing price
of $17.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.38       -0.40      -0.41     Missed  -3.5
 Jun. 30 2023  -0.40       -0.40      -0.34     Beat    14.6
 Mar. 31 2023  -0.35       -0.36      -0.36     Met     0​
 Dec. 31 2022  -0.34       -0.34      -0.31     Beat    7.7
 ​​Sep.        -0.35       -0.36      -0.34     Beat    4.5
 30 2022                                                
 Jun. 30 2022  -0.33       -0.32      -0.32     Met     1.2​
 Mar. 31 2022  -0.28       -0.28      -0.30     Missed  -7.9
 Dec. 31 2021  -0.24       -0.25      -0.26     Missed  -5.1
 This summary was machine generated February 19 at 14:15 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)